p.90 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e361 CLINICAL STATEMENTS AND GUIDELINES

Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–90. S4.3.2-10.	Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40. S4.3.2-11.	Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. S4.3.2-12.	Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985;71:63–71. S4.3.2-13.	Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440–7. S4.3.2-14.	Giustetto C, Schimpf R, Mazzanti A, et al. Long-term followup of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587–95. S4.3.2-15.	Mahida S, Derval N, Sacher F, et al. Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015;65:151–9. S4.3.2-16.	Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69–74. S4.3.2-17.	Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2013;6:504–12. S4.3.2-18.	Brembilla-Perrot B, Suty-Selton C, Beurrier D, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing. J Am Coll Cardiol. 2004;44:594–601. S4.3.2-19.	Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866–72. S4.3.2-20.	Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006;296:1249–54. S4.3.2-21.	Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490–500. S4.3.2-22.	Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm. 2008;5:831–6. S4.3.2-23.	Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation. 2001;104:557–62. S4.3.2-24.	Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300–8. S4.3.2-25.	Wong JA, Gula LJ, Klein GJ, et al. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome. Circ Arrhythm Electrophysiol. 2010;3:120–5. S4.3.2-26.	Walker BD, Krahn AD, Klein GJ, et al. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. Am Heart J. 2005;150:1059–63. S4.3.2-27.	Waks JW, Sitlani CM, Soliman EZ, et al. Global electric heterogeneity risk score for prediction of sudden cardiac death in the general population: the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Circulation. 2016;133:2222–34. S4.3.2-28.	Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with betablockers. JAMA. 2004;292:1341–4. S4.3.2-29.	Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–74. S4.3.2-30.	Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107–15. S4.3.2-31.	Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51–9. S4.3.2-32.	Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher-

ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183–9. 5 THERAPIES FOR TREATMENT OR

PREVENTION OF VA

5.1 Medication Therapy

S5.1.5.2-1.	 Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129–47. S5.1.5.2-2.	 Schleifer JW, Sorajja D, Shen WK. Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opin Pharmacother. 2015;16:2637–51. S5.1.5.2-3.	 Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711–22. S5.1.5.2-4.	 Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053–8. S5.1.5.2-5.	 Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–3. S5.1.5.2-6.	 Gupta T, Khera S, Kolte D, et al. Antiarrhythmic properties of ranolazine: a review of the current evidence. Int J Cardiol. 2015;187:66–74. S5.1.5.2-7.	 Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600–6. S5.1.5.2-8.	 Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non- ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122:455–62. S5.1.5.2-9.	 Zareba W, Daubert JP, Beck CA, et al. Ranolazine in High-Risk ICD Patients (RAID) Trial. Presented at: Heart Rhythm Society Annual Scientific Sessions. 2017; LBCT02–01. S5.1.5.2-10.	 Reiter MJ, Reiffel JA, Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 1998;82:9I–19I. S5.1.5.2-11.	 Ellison KE, Hafley GE, Hickey K, et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation. 2002;106:2694–9. S5.1.5.2-12.	 Reiken S, Wehrens XH, Vest JA, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003;107:2459–66. S5.1.5.2-13.	 MERIT-HF Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7. S5.1.5.2-14.	 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55. S5.1.5.2-15.	 Committees of the Cardiac insufficiency Bisoprolol Study II. The cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. S5.1.5.2-16.	 A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA. 1982;247:1707–14. S5.1.5.2-17.	 Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute betablocker therapy: results from the American College of Cardiology’s NCDR(R). Am Heart J. 2011;161:864–70. S5.1.5.2-18.	 Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life supportguided therapy. Circulation. 2000;102:742–7. S5.1.5.2-19.	 Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S5.1.5.2-20.	 Hirsowitz G, Podrid PJ, Lampert S, et al. The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J. 1986;111: 852–60. S5.1.5.2-21.	 Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J

Cardiol. 1999;84:90R–3R.

Downloaded from http://ahajournals.org by on October 7, 2026